The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.
 
Marcello Tiseo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Otsuka; Pierre Fabre
 
Luca Boni
Research Funding - AMGEN (Inst)
Patents, Royalties, Other Intellectual Property - International Patent nr. PCT/EP2012/065661
 
Francesca Ambrosio
No Relationships to Disclose
 
Andrea Camerini
Consulting or Advisory Role - AstraZeneca; Pfizer; Pierre Fabre; Roche/Genentech
 
Editta Baldini
No Relationships to Disclose
 
Saverio Cinieri
No Relationships to Disclose
 
Francesca Zanelli
No Relationships to Disclose
 
Efisio Defraia
No Relationships to Disclose
 
Matteo Brighenti
No Relationships to Disclose
 
Lucio Crino
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis
 
Claudio Dazzi
No Relationships to Disclose
 
Carmelo Tibaldi
No Relationships to Disclose
 
Gianni Michele Turolla
No Relationships to Disclose
 
Vito D'Alessandro
No Relationships to Disclose
 
Nicoletta Zilembo
No Relationships to Disclose
 
Anna Rita Trolese
No Relationships to Disclose
 
Francesco Grossi
No Relationships to Disclose
 
Ferdinando Riccardi
No Relationships to Disclose
 
Andrea Ardizzoni
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD Oncology